Yaoyuan Biotechnology

Yaoyuan Biotechnology is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the development of innovative mRNA-based vaccines and therapeutics. The company leverages a proprietary mRNA synthesis and lipid nanoparticle (LNP) delivery platform to address significant unmet needs in infectious diseases and oncology. Its lead candidate, YY-001, is an mRNA vaccine targeting COVID-19 that has entered clinical trials, while its broader pipeline includes programs for seasonal influenza and various cancer indications. Yaoyuan integrates advanced R&D with large-scale GMP manufacturing capabilities to ensure the rapid translation of mRNA technology into clinical solutions. The company is supported by prominent venture capital firms, including Legend Capital and GL Ventures.